Novel vaccines based on the ADDomer™ to provide protection against infectious disease wherever it affects human health worldwide.

​

Imophoron is a pre-clinical stage company with a novel vaccine platform called ADDomer. ADDomer is a patented technology for creating highly immunogenic vaccine candidates and is an adenovirus-derived, multimeric protein-based, self-assembling nanoparticle scaffold. Proof of concept data for two highly infectious diseases demonstrate potential to prevent disease and transmission.